BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015;28:418-23. [PMID: 26382168 DOI: 10.1097/YCO.0000000000000198] [Cited by in Crossref: 68] [Cited by in F6Publishing: 18] [Article Influence: 13.6] [Reference Citation Analysis]
2 Andersen RL, Johnson DJ, Patel JN. Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. Pharmacogenomics 2016;17:417-34. [PMID: 26871520 DOI: 10.2217/pgs.15.178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol 2016;14:191-9. [PMID: 26572745 DOI: 10.2174/1570159x14666151117122458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
4 Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? Lancet Psychiatry. 2017;4:409-418. [PMID: 28153641 DOI: 10.1016/s2215-0366(17)30015-9] [Cited by in Crossref: 171] [Cited by in F6Publishing: 72] [Article Influence: 42.8] [Reference Citation Analysis]
5 Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol 2018;8:13-23. [PMID: 29344340 DOI: 10.1177/2045125317720642] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
6 Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother 2017;18:1011-7. [PMID: 28535081 DOI: 10.1080/14656566.2017.1334765] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
7 Lochmann D, Richardson T. Selective Serotonin Reuptake Inhibitors. Handb Exp Pharmacol 2019;250:135-44. [PMID: 30838457 DOI: 10.1007/164_2018_172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Ragi NC, Velma GR, Pallerla PK, Siddiqua S, Alugonda V, Rachamalla HKR, Pabbaraja S, Sripadi P. Identification and characterization of forced degradation products of vortioxetine by LC/MS/MS and NMR. J Pharm Biomed Anal 2020;188:113442. [PMID: 32622114 DOI: 10.1016/j.jpba.2020.113442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Safer DJ. Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events. J Clin Psychopharmacol 2016;36:483-91. [PMID: 27518478 DOI: 10.1097/JCP.0000000000000564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 14.6] [Reference Citation Analysis]
11 Karrouri R, Hammani Z, Benjelloun R, Otheman Y. Major depressive disorder: Validated treatments and future challenges. World J Clin Cases 2021; 9(31): 9350-9367 [DOI: 10.12998/wjcc.v9.i31.9350] [Reference Citation Analysis]
12 Ślifirski G, Król M, Turło J. 5-HT Receptors and the Development of New Antidepressants. Int J Mol Sci 2021;22:9015. [PMID: 34445721 DOI: 10.3390/ijms22169015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kang A, Xie T, Zhu D, Shan J, Di L, Zheng X. Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice. J Agric Food Chem 2017;65:6861-9. [PMID: 28762741 DOI: 10.1021/acs.jafc.7b02386] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
14 Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol 2017;8:643. [PMID: 28955242 DOI: 10.3389/fphar.2017.00643] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
15 Peckham AM, De La Cruz A, Dufresne RL. Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression? Ment Health Clin 2018;8:175-83. [PMID: 30155392 DOI: 10.9740/mhc.2018.07.175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
16 Deardorff WJ, Grossberg GT. The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Curr Geri Rep 2015;4:301-11. [DOI: 10.1007/s13670-015-0140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y, Zheng Q, Li L. Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. Int J Neuropsychopharmacol 2020;23:76-87. [PMID: 31774497 DOI: 10.1093/ijnp/pyz062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
18 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
19 Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi‐shabestari A, Akhondzadeh S. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. J Clin Pharm Ther 2020;45:804-11. [DOI: 10.1111/jcpt.13177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. J Affect Disord 2018;228:1-12. [PMID: 29197738 DOI: 10.1016/j.jad.2017.11.056] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
21 Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 2016;12:541-57. [PMID: 27042068 DOI: 10.2147/NDT.S91311] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 5.2] [Reference Citation Analysis]